Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Hohenberger et al.|The Lancet|2012Cited by 1.4k
Secondary mutations in the kinase domain of the <i> KIT</i> gene are predominant in imatinib‐resistant gastrointestinal stromal tumorToshirou Nishida, Seiichi Hirota|Cancer Science|2008Cited by 111
Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumorsYuuki Obata, Ryo Abe, Keita Horikawa et al.|Oncogene|2017Cited by 47